Enlivex Therapeutics receives FDA clearance for Allocetra IND

Enlivex Therapeutics announced that the U.S. Food & Drug Administration has cleared an Investigational New Drug application to study Allocetra in patients with advanced solid malignancies. The FDA’s Phase I/II clearance follows a recent announcement by the Company that the first patient has been dosed in a Phase I/II multi-center clinical trial in Israel designed to evaluate the safety, tolerability and preliminary efficacy of Allocetra stand-alone, and in combination with a PD1 checkpoint inhibitor, in patients with advanced solid tumors.